Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 07:00PM GMT
Release Date Price: MXN1862.61
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're pleased to have with us Ultragenyx with Emil Kakkis, CEO and Mardi Dier, CFO. Thanks for joining, Emil.

Questions & Answers

Salveen Jaswal Richter;Emil D. Kakkis
Goldman Sachs Group, Inc., Research Division - VP;Ultragenyx Pharmaceutical Inc. - President, CEO &

And maybe to start here, I was going to ask some big platform questions, but I might start with Angelman just given the news that, that hit.

So you reported this morning that the U.K. Medicines and Healthcare products Regulatory Agency approved the CTA for the Phase I/II study in pediatric patients. And you've also received clearance to enroll patients in Canada. And -- I believe, and you're expecting to enroll them in the second half of this year with clinical data for some patients by year-end. Maybe help us understand what this means to start and then we can walk into next steps?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot